Catalyst Edge · Scanner · Tickers · BMY
CATALYST DOSSIER · UPDATED 2026-11-05

$BMY

pharma · convergence 7 · conviction WATCH
Convergence Score
7
Conviction
WATCH
Signals Firing
9
Quick tools:🃏 Swipe deck🎯 Today verdict

Price & Live Quote

Loading live quote & chart…

Practice trade tools

Build a reference frame, save a practice trade, or preview a draft. No brokerage order is placed.

Paper trade unavailable: missing risk-bounded frame

Reference only. Not financial advice. No brokerage order is placed.

Why $BMY?

BMY 7 WATCH pharma

Quantitative

  • Convergence score: 7 (9 signals firing YoY)

Catalysts

  • Clinical trial milestone: Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
  • Clinical trial milestone: A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovaria

Risks

  • Position-sizing discipline: Conviction WATCH (7 score) — size accordingly; no specific catalyst-fade risk flagged

Bear case

  • Multiple compression: If breadth deteriorates, pharma-wide multiples re-rate lower regardless of pick-specific thesis

Sympathy basket (cerebro)

  • AMGN via pharma r=+0.00 intra-sector (score 13)
  • ABBV via pharma r=+0.00 intra-sector (score 5)
  • XBI via pharma r=+0.00 intra-sector (score 2)
  • IBB via pharma r=+0.00 intra-sector (score 1)
  • GILD via pharma r=+0.00 intra-sector (score 0)
  • JNJ via pharma r=+0.00 intra-sector (score 0)

Signals Firing

clinicalfda_appmacroorphan_leanoge_execbiotechauto_macro_adp_payrollsauto_macro_durable_goodsauto_macro_fx_rates
Each tag is a spoke that flagged this ticker today. Weights tuned weekly against published outcomes.

Sympathy Basket

Tickers Catalyst Edge tracks as moving with this name. Cross-correlation derived from sector + score-cohort proximity.

Earnings Catalyst

No recent earnings event.

Auto-generated from public filings + tier-1 wires. Catalyst Edge publishes its picks and its losses — see the trust report and methodology. Not financial advice. Confirm independently before trading.

You came here for BMY. You found it after it moved, the same way everyone else did.

$99 once — every ticker on this site ranked before the open.

Review the methodology and limitations and the dated audit. An intraday price touch is not trading profit.

  1. Click Become a Founding Member below.
  2. Pay $99 once — not monthly, not ever again.
  3. You keep every future release at that price. Tomorrow's ranked list lands at 3:30 AM ET, before the open.
Become a Founding Member — $99 once

One payment, access for as long as we run the service. The free daily picks stay free — this is for people who want the full console. Not buying today? Get tomorrow's ranked list free →

Optional product-learning preferences